These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18165785)

  • 1. Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis.
    Bharat A; Narayanan K; Golocheikine A; Steward N; Crippin J; Lisker-Melman M; Shenoy S; Lowell J; Chapman WC; Mohanakumar T
    Transplantation; 2007 Dec; 84(12):1704-7. PubMed ID: 18165785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated CD4+/CD25+ T-cell frequency and function during hepatitis C virus recurrence after liver transplantation.
    Perrella A; Arenga G; Pisaniello D; Rampone B; Di Costanzo GG; Atripaldi L; Esposito C; Di Florio E; Perrella O; Cuomo O
    Transplant Proc; 2009 Jun; 41(5):1761-6. PubMed ID: 19545723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection.
    Schirren CA; Jung M; Worzfeld T; Mamin M; Baretton GB; Gruener NH; Gerlach JT; Diepolder HM; Zachoval R; Pape GR
    Liver Transpl; 2000 Mar; 6(2):222-8. PubMed ID: 10719024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pre- and posttransplantation serum interferon-gamma and soluble CD30 for predicting liver allograft rejection.
    Kim KH; Oh EJ; Jung ES; Park YJ; Choi JY; Kim DG; Lee KY; Kang CS
    Transplant Proc; 2006 Jun; 38(5):1429-31. PubMed ID: 16797323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
    Solgi G; Amirzagar AA; Pourmand G; Mehrsai AR; Taherimahmoudi M; Baradaran N; Nicknam MH; Ebrahimi Rad MR; Saraji A; Asadpoor AA; Moheiydin M; Nikbin B
    Transplant Proc; 2009 Sep; 41(7):2800-4. PubMed ID: 19765439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune response to hepatitis C after liver transplantation: assessment of a new recombinant immunoblot assay.
    Rosen HR; Gretch D; Kaufman E; Quan S
    Am J Gastroenterol; 2000 Aug; 95(8):2035-9. PubMed ID: 10950054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra portal donor specific antigen transfusion might prevent re-infection of hepatitis C virus after living related liver transplantation in hepatitis C hepatic cirrhosis.
    Sato Y; Oya H; Yamamoto S; Kobayashi T; Watanabe T; Kokai H; Yamagiwa S; Hatakeyama K
    Hepatogastroenterology; 2009; 56(89):205-7. PubMed ID: 19453058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of INF-gamma, TNF-alpha and dendritic cells to predict hepatitis C virus recurrence in liver transplant patients.
    Ocaña L; Cos J; Quer J; Bilbao I; Palou E; Parra R; Sauleda S; Esteban JI; Guàrdia J; Massuet LI; Margarit C
    Transplant Proc; 2005 Nov; 37(9):3951-6. PubMed ID: 16386594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate.
    Pelletier SJ; Raymond DP; Crabtree TD; Berg CL; Iezzoni JC; Hahn YS; Sawyer RG; Pruett TL
    Hepatology; 2000 Aug; 32(2):418-26. PubMed ID: 10915752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of recurrent HCV infection after liver transplantation].
    Ostojić R
    Acta Med Croatica; 2005; 59(5):443-6. PubMed ID: 16381241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement.
    Truong DQ; Darwish AA; Gras J; Wieërs G; Cornet A; Robert A; Mourad M; Malaise J; de Ville de Goyet J; Reding R; Latinne D
    Transpl Immunol; 2007 Jun; 17(4):283-7. PubMed ID: 17493532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence.
    Micheloud D; Salcedo M; Bañares R; Rincón D; Lorente R; Muñoz-Fernández MA; Resino S
    Transpl Infect Dis; 2009 Apr; 11(2):183-8. PubMed ID: 19254326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor-specific hyporesponsiveness in ELISPOT assay is associated with early recurrence of hepatitis C in liver transplant recipients.
    Tambur AR; Ben-Ari Z; Herrera ND; Klein T; Michowiz R; Mor E
    Hum Immunol; 2005 Jan; 66(1):21-7. PubMed ID: 15620458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of virus-specific T-cell immunity in liver allograft recipients with HCV-induced cirrhosis.
    Bharat A; Barros F; Narayanan K; Borg B; Lisker-Melman M; Shenoy S; Lowell J; Crippin J; Chapman W; Mohanakumar T
    Am J Transplant; 2008 Jun; 8(6):1214-20. PubMed ID: 18522547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of soluble CD30 in liver transplantation.
    Fábrega E; Unzueta MG; Cobo M; Casafont F; Amado JA; Romero FP
    Transplant Proc; 2007 Sep; 39(7):2295-6. PubMed ID: 17889168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of HCV-specific CD4+Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis.
    Basha HI; Subramanian V; Seetharam A; Nath DS; Ramachandran S; Anderson CD; Shenoy S; Chapman WC; Crippin JS; Mohanakumar T
    Am J Transplant; 2011 Apr; 11(4):775-85. PubMed ID: 21446979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble CD30 serum level in HCV-positive chronic active hepatitis: A surrogate marker of disease activity?
    Foschi FG; Gramenzi A; Castelli E; Cursaro C; Pagani S; Margotti M; D'Errico A; Andreone P; Stefanini GF; Bernardi M
    Cytokine; 2000 Jun; 12(6):815-8. PubMed ID: 10843771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and management of hepatitis C in liver transplant recipients.
    Chan SE; Rosen HR
    Clin Infect Dis; 2003 Sep; 37(6):807-12. PubMed ID: 12955642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
    Briceño J; Ciria R; Pleguezuelo M; de la Mata M; Muntané J; Naranjo A; Sánchez-Hidalgo J; Marchal T; Rufián S; López-Cillero P
    Liver Transpl; 2009 Jan; 15(1):37-48. PubMed ID: 19109846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication.
    Ciuffreda D; Comte D; Cavassini M; Giostra E; Bühler L; Perruchoud M; Heim MH; Battegay M; Genné D; Mulhaupt B; Malinverni R; Oneta C; Bernasconi E; Monnat M; Cerny A; Chuard C; Borovicka J; Mentha G; Pascual M; Gonvers JJ; Pantaleo G; Dutoit V
    Eur J Immunol; 2008 Oct; 38(10):2665-77. PubMed ID: 18958874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.